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Objective To develop a core outcome set for pre-eclampsia.
Design Consensus development study.
Setting International.
Population Two hundred and eight-one healthcare professionals,
41 researchers and 110 patients, representing 56 countries,
participated.
Methods Modified Delphi method and Modified Nominal Group
Technique.
Results A long-list of 116 potential core outcomes was developed
by combining the outcomes reported in 79 pre-eclampsia trials
with those derived from thematic analysis of 30 in-depth
interviews of women with lived experience of pre-eclampsia.
Forty-seven consensus outcomes were identified from the Delphi
process following which 14 maternal and eight offspring core
outcomes were agreed at the consensus development meeting.
Maternal core outcomes: death, eclampsia, stroke, cortical
blindness, retinal detachment, pulmonary oedema, acute kidney
injury, liver haematoma or rupture, abruption, postpartum
haemorrhage, raised liver enzymes, low platelets, admission to
intensive care required, and intubation and ventilation. Offspring
core outcomes: stillbirth, gestational age at delivery, birthweight,
small-for-gestational-age, neonatal mortality, seizures, admission
to neonatal unit required and respiratory support.
Conclusions The core outcome set for pre-eclampsia should underpin
future randomised trials and systematic reviews. Such implementation
should ensure that future research holds the necessary reach and
relevance to inform clinical practice, enhance women’s care and
improve the outcomes of pregnant women and their babies.
Keywords Consensus development study, core outcome set,
modified Delphi method, modified nominal group technique,
outcome reporting bias, pre-eclampsia.
Tweetable abstract @HOPEoutcomes 281 healthcare professionals,
41 researchers and 110 women have developed #preeclampsia
@jamesmnduffy.
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Introduction
When untreated, pre-eclampsia is life-threatening, and in
low- and middle-income countries it is one of the leading
causes of maternal mortality, severe maternal morbidity
and stillbirth.1 The development of effective and safe
treatments for pre-eclampsia is urgently needed. Potential
treatments should be evaluated in randomised trials, and
to ensure the greatest gains in reducing the current bur-
den of mortality and severe morbidity associated with
pre-eclampsia, research should be undertaken in all set-
tings, including low- and middle-income countries. Several
national and international organisations, including the
World Health Organization, have prioritised over 50
unanswered research questions relating to the evaluation
of potential treatments for pre-eclampsia.2–4 However,
complex issues including a failure to consider the perspec-
tives of women with lived experience of pre-eclampsia
when designing randomised trials, variations in outcome
measures and outcome reporting bias, could undermine
the translation of future pre-eclampsia research into clini-
cal practice.5 Such research waste represents a substantial
barrier to improving the care that women and their
babies receive.
A recent systematic review characterised outcome report-
ing across published pre-eclampsia trials.6 This systematic
evaluation illustrated the widespread variation in the
reporting of maternal and offspring outcomes. Most pre-
eclampsia trials did not report information on clinically
important outcomes, including stroke, liver failure and
renal failure, and did not evaluate efficacy and safety in the
participants’ infants, particularly over the longer term.
The challenges of poor outcome selection, measurement
and reporting can be addressed by developing, disseminat-
ing and implementing a core outcome set for future pre-
eclampsia research.7 A core outcome set represents a mini-
mum dataset, developed using robust consensus science
methods, engaging diverse stakeholders including health-
care professionals, researchers and patients.7,8 Core out-
comes should be routinely used by researchers, collected in
a standardised manner and reported consistently in the
final publication allowing comparability between individual
randomised trials and efficient meta-analysis.7,9
The objective of this study was to develop a clinically rel-
evant core data set to standardise outcome selection, collec-
tion and reporting across future randomised trials and
systematic reviews evaluating potential treatments for pre-
eclampsia.
Methods
The study was prospectively registered with the Core Out-
come Measures in Effectiveness Trials (COMET) Initiative,
registration number 588. A protocol with explicitly defined
objectives, formal consensus development methods, criteria
for participant identification and selection, and statistical
methods has been published.10
An international steering group, including healthcare
professionals, researchers and women with lived experience
of pre-eclampsia, was established to provide a perspective
to inform key methodological decisions. The core outcome
set was developed in a three-stage process using consensus
science methods advocated by the COMET initiative.7
There is no international consensus regarding the diag-
nostic criteria for pre-eclampsia. The study did not seek to
reach consensus regarding the definition of pre-eclampsia
and adopted the International Society for the Study of
Hypertension in Pregnancy’s pre-eclampsia definition,
which is defined as gestational hypertension presenting
with new-onset proteinuria, other maternal organ dysfunc-
tion and/ or uteroplacental dysfunction.11 This study is
complementary to the work of the Global Pregnancy Col-
laboration and the International Society for the Study of
Hypertension in Pregnancy who are engaged with the stan-
dardisation of other aspects of study design, the develop-
ment of a standardised database for perinatal research
studies and the development of clinical practice guidelines.
Potential core outcomes were identified by extracting
outcomes reported in published pre-eclampsia trials and
undertaking a thematic analysis of in-depth interviews with
women with lived experience of pre-eclampsia. Both studies
have been published.6,12 A comprehensive inventory of out-
comes and plain-language descriptions was developed in
consultation with the study’s steering group. This inventory
was entered into a modified Delphi method, which was
delivered through sequential online surveys using Delphi
survey software (DELPHIMANAGER, University of Liverpool,
Liverpool, UK).
Healthcare professionals, researchers and women with
lived experience of pre-eclampsia were invited to participate.
Healthcare professionals were recruited through the Core
Outcomes in Women’s and Newborn Health (CROWN) ini-
tiative, Global Obstetrics Network and the International
Society for the Study of Hypertension in Pregnancy.
Researchers were recruited through participation in ongoing
pre-eclampsia research studies including: (1) community
blood pressure monitoring in rural Africa and Asia;13 (2)
detection of underlying pre-eclampsia study, development
and validation of a prediction model for risk of complica-
tions in early-onset pre-eclampsia study;14 (3) international
prediction of pre-eclampsia individual patient data collabo-
rative network and (4) pre-eclampsia: eclampsia monitoring,
prevention and treatment initiative.15 Women with lived
experience of pre-eclampsia were recruited through patient
organisations including Action on Pre-eclampsia; Count the
Kicks; Group B Strep Support and Tommy’s. The Delphi
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method does not depend on statistical power and between 10
and 15 participants has been demonstrated to yield sufficient
results.16–18 The study aimed to recruit at least 18 partici-
pants for each stakeholder group but planned to maximise
the number to increase generalisability, anticipating an over-
all attrition rate of 20%.
The round 1 survey was piloted by the study’s steering
group before use. Feedback was specifically sought regard-
ing the survey instructions, ease of completion, the appro-
priateness of terminology and time taken to complete the
survey. The survey was adjusted in response to feedback.
Before entering the round 1 survey, participants received
an explanatory video abstract, a plain-language summary
and survey instructions, provided demographic details and
made an explicit commitment to complete all three rounds.
Following registration, a unique identifier was generated
and allocated to each participant, to ensure that future
responses were both linked and anonymised. In round 1,
participants scored individual outcomes on a nine-point
Likert scale.19 Participants were able to select an ‘unable to
score’ category if they did not feel they had sufficient
expertise or experience to score an individual outcome.
Before completing the survey, participants were able to sug-
gest additional outcomes. After the round 1 survey had
closed, the scores for each outcome were aggregated across
individual stakeholder groups. The percentage of partici-
pants scoring each outcome at every possible response from
one to nine was calculated by the Delphi survey software
and tabulated for individual stakeholder groups. Suggested
additional outcomes were reviewed by the steering group
and unique outcomes were entered into round 2.
In round 2, participants received their own scores and
individual stakeholder group feedback for each round 1 out-
come. Participants were asked to reflect on their own scores
and on the scores of other participants, before re-scoring
each outcome. Before completing the survey, participants
were able to score additional outcomes suggested by partici-
pants in the round 1 survey. After the round 2 survey had
closed, the percentage of participants scoring each outcome
at every possible response from one to nine was calculated
and tabulated for individual stakeholder groups.
In round 3, participants received their own scores and
individual stakeholder group feedback for each round 2 out-
come. Participants were asked to reflect on their own scores
and on the scores of other participants before re-scoring each
outcome. After the round 3 survey had closed, it was agreed
before review of the results that a consensus definition would
be identified when >70% of participants in each stakeholder
group scored the outcome ‘critical for decision-making’
(score seven to nine) and <15% of participants in each stake-
holder group scored the outcome ‘of limited importance for
decision-making’ (score one to three).7 Participants who
withdrew from the Delphi survey were requested to complete
an anonymous online questionnaire providing free-text com-
ments outlining their reason(s) for withdrawing. These
responses were coded and summarised.
With regard to the other consensus method used in the
study, the modified nominal group technique was delivered
through a half-day consensus development meeting.18
Healthcare professionals, researchers and women with lived
experience of pre-eclampsia, resident in the UK and who
had completed all three rounds of the Delphi survey were
invited to participate in a consensus development meeting.
Anyone who responded favourably was extended an invita-
tion to attend the consensus development meeting. The
modified nominal group technique does not depend on
statistical power and there is no robust method for calcu-
lating the required number of participants. The study
aimed to recruit between 10 and 15 participants as this
number has assured validity in other settings.18,20
Before the meeting, participants provided demographic
details and made an explicit commitment to participate
actively. All consensus outcomes were entered into the pro-
cess. Participants were able to enter other outcomes which
had not reached the consensus threshold, upon request.
Following an initial discussion, outcomes were divided into
three provisional categories: (1) outcomes to be considered
for inclusion in the final core outcome set, (2) outcomes
where no consensus existed and (3) outcomes that should
not be considered for inclusion in the final core outcome
set. Participants were invited to discuss the ordering of the
outcomes within each category, considering contextual
information, including the relative importance of individual
outcomes, feasibility to collect the outcome data and the
availability of suitable definitions and measurement instru-
ments. They were encouraged to reformulate outcomes to
improve clarity or comprehension. The discussion focused
upon ranking the outcomes being considered for inclusion
in the final core outcome set and the outcomes where no
consensus existed. During the discussion, the outcomes
could be moved between the categories. Finally, the core
outcome set was agreed.
Descriptive statistics were used to describe participant
demographics. Medians (~x), interquartile ranges (IQR) and
scoring distributions were calculated across individual
stakeholder groups (healthcare professionals, researchers
and patients) and pooled across individual outcomes. The
skewness of each scoring distribution was calculated using
Pearson’s coefficient of skewness (Sk2). All analyses were
performed using GRAPHPAD PRISM (GraphPad, San Diego,
CA, USA).
The study was funded by the National Institute for
Health Research, Barts Charity and Elisabeth Garrett
Anderson Hospital Charity Travelling Fellowship in Mem-
ory of Anne Boutwood, Royal College of Obstetricians and
Gynaecologists.
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Results
Seventy-nine pre-eclampsia trials reported 106 different
outcomes and thematic analysis of 30 in-depth interviews
with women with lived experience of pre-eclampsia identi-
fied 71 outcomes (Figure 1).6,12 Combining these resulted
in 116 unique outcomes, which were entered into the Del-
phi survey.21
The Delphi survey was started by 281 healthcare profes-
sionals, 41 researchers and 110 women with lived experience
of pre-eclampsia, representing 31 high-income countries and
25 low- and middle-income countries (Table 1). Over the
three Delphi survey rounds, 159 participants (37%) with-
drew, including 100 healthcare professionals (35%), 11
researchers (27%) and 48 patients (44%). The majority of
participants who withdrew from the survey provided an
explanation (see Supplementary material, Table S1). In
response to the outcomes suggested by participants, the
steering group recommended the reformulation of 11 out-
comes to improve clarity and added 20 new outcomes to
round 2 (see Supplementary material, Figure S1). Therefore,
136 outcomes were subsequently entered into rounds 2 and
Systematic review
107 potential core outcomes
Qualitative patient interviews
70 potential core outcomes
116 potential core outcomes
136 potential core outcomes scored
136 potential core outcomes scored
Delphi survey round 1
281 healthcare professionals
41 researchers
110 patients
Delphi survey round 2
201 healthcare professionals
37 researchers
72 patients
Delphi survey round 3
181 healthcare professionals
30 researchers
62 patients
11 outcomes reformulated
20 additional outcomes entered
Consensus meeting
11 healthcare professionals
2 researchers
3 patients
Core outcome set for pre-eclampsia
47 consensus outcomes entered
Final consensus
Nine consensus outcomes reformulated
Four outcomes entered by participants
85 outcomes not progressed further
Figure 1. Flow of participants and outcomes.
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3. In round 3 results, 47 outcomes reached the consensus
threshold (see Supplementary material, Appendix S1).
The consensus development meeting included 11 health-
care professionals, two researchers and four women with
lived experience of pre-eclampsia. Nine participants (56%)
had lived, worked or conducted research in low- or mid-
dle-income countries. Forty-seven consensus outcomes
were considered using the modified nominal group tech-
nique. Participants recommended the reformulation of nine
consensus outcomes and entered an additional four no
consensus outcomes into the process.
Participants prioritised 22 outcomes, comprising 14
maternal and eight offspring outcomes, for inclusion in the
core outcome set for pre-eclampsia (Table 2). Outcomes
represented maternal and infant mortality and severe mor-
bidity. These included maternal mortality, stroke, pul-
monary oedema, acute kidney injury, placental abruption
and postpartum haemorrhage. Outcomes demonstrating
the impact of pre-eclampsia on the fetus and neonate
included stillbirth and neonatal mortality, gestational age at
delivery and birthweight, and neonatal seizures. Finally,
outcomes representing the resource utilisation resulting
from the management of severe maternal and neonatal
morbidity included the requirement for maternal admission
to intensive care, the requirement for neonatal unit admis-
sion and respiratory support.
Discussion
Main findings
Using robust consensus science methods, healthcare profes-
sionals, researchers and women with experience of pre-
eclampsia have developed a core outcome set to standardise
outcome selection, collection and reporting across future
pre-eclampsia trials and systematic reviews.
Strengths and limitations
This study has met the recently published standards for core
outcome set development, developed by an international
Table 1. Participant characteristics
Delphi survey Consensus
development
meeting
Round
1
n = 432
Round
2
n = 310
Round
3
n = 273
n = 16
Stakeholder group, n (%)
Patients 110 (25) 72 (23) 62 (23) 4 (25)
Healthcare
professionals
281 (65) 201 (65) 181 (66) 11 (69)
Anaesthetists 39 (9) 30 (10) 28 (10) 2 (13)
General
practitioners
42 (10) 34 (11) 31 (11) 2 (13)
Midwives 35 (8) 30 (10) 27 (10) 3 (19)
Neonatologists
or paediatricians
24 (6) 17 (5) 15 (5) 1 (6)
Obstetricians 113 (26) 72 (23) 65 (24) 2 (13)
Physicians 28 (6) 18 (6) 15 (5) 1 (6)
Researchers 41 (9) 37 (12) 30 (11) 2 (13)
Gender, n (%)
Male 154 (36) 114 (37) 101 (37) 7 (44)
Female 277 (64) 195 (63) 171 (63) 10 (56)
Prefer not to say 1 (<1) 1 (<1) 1 (<1)
Age (years), n (%)
20–29 16 (3) 10 (3) 9 (3) 1 (6)
30–39 159 (37) 111 (36) 103 (38) 6 (38)
40–49 113 (26) 79 (25) 74 (27) 4 (25)
50–59 84 (19) 63 (20) 60 (11) 4 (25)
60–69 54 (13) 41 (13) 22 (8) 1 (6)
Over 70 4 (<1) 4 (1) 4 (1) 1 (6)
Prefer not to say 2 (<1) 2 (<1) 1 (<1) 0 (0)
Geographical location, n (%)
Africa 20 (5) 17 (5) 16 (6) 0 (0)
Asia 26 (6) 14 (5) 13 (5) 0 (0)
Australia 35 (8) 28 (9) 23 (8) 0 (0)
Europe 237 (55) 175 (56) 159 (58) 16 (100)
Middle East 7 (2) 4 (13) 4 (1) 0 (0)
North America 82 (19) 58 (19) 47 (17) 0 (0)
South America 23 (5) 13 (4) 11 (4) 0 (0)
Prefer not to say 2 (<1) 1 (<1) 0 (0) 0 (0)
Table 2. Core outcome set for pre-eclampsia
Maternal core outcomes
Maternal mortality
Eclampsia
Stroke
Cortical blindness
Retinal detachment
Pulmonary oedema
Acute kidney injury
Liver capsule haematoma or rupture
Placental abruption
Postpartum haemorrhage
Raised liver enzymes
Low platelets
Admission to intensive care unit required
Intubation and mechanical ventilation (not for childbirth)
Offspring outcomes
Stillbirth
Gestational age at delivery
Birthweight
Small-for-gestational-age
Neonatal mortality
Neonatal seizures
Admission to neonatal unit required
Respiratory support
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group of experienced core outcome set developers, method-
ologists and potential core outcome set end users.22 By meet-
ing these recommendations, this study has objectively
demonstrated its methodological quality. When considering
core outcome set development, a high number of diverse
participants is desirable to secure the generalisability of the
results and increase its credibility with other researchers.
With over 400 participants from 56 countries, the global par-
ticipation achieved in this study should secure the relevance
of the results across an international context. The core out-
come set for pre-eclampsia is perceived as an exemplar of
core outcome set development and the study’s approach has
been adopted by many other core outcome set development
studies.23–26
This consensus study is not without limitations. There is
considerable uncertainty regarding core outcome set devel-
opment methods.27 The optimal approaches to selecting
participants, structuring interaction embedded in different
consensus methods, including modified Delphi method,
modified Nominal Group Technique and consensus devel-
opment conference, and methods of synthesising individual
judgements. Further methodological research is required to
inform future core outcome set development.
When considering the Delphi survey, there was a higher
response from participants who identified as white (83%),
living in Europe (55%) and living in high-income countries
(82%). To participate in the Delphi survey, English profi-
ciency, a computer and internet access were required. Limi-
tations in the representativeness of the sample could have
impacted upon the outcomes prioritised; however, given
the wide range of outcomes from the previous worldwide
literature that fed into the process, this should not have
been a major issue.
The study’s attrition rate was 37%, which is comparable to
other core outcome set development studies in health of
women and neonates.8 This did vary between stakeholder
groups with more patients (44%) dropping out than other
groups, such as healthcare professionals (35%) and research-
ers (27%). It may have been possible to reduce attrition, par-
ticularly within the patient stakeholder group, by reducing
the length of the survey. However, attrition needed to be bal-
anced with the requirement to enter a comprehensive long-
list of potential core outcomes into the Delphi survey and for
participants to be able to reflect on and re-score individual
outcomes in relation to each other.
Although the notion of achieving consensus is funda-
mental to core outcome set development, the definition of
what constitutes consensus is less clear. The pre-specified
consensus definition applied within the Delphi survey
could be considered as being too accommodating, as it
resulted in the identification of 47 initial consensus out-
comes. Further methodological research is required to
develop an appropriate consensus definition that could
accommodate the skewed scoring distribution of the
respondents.28
Interpretation
Most trials evaluating potential treatments for pre-eclamp-
sia have neglected to report many of the outcomes
included in the core outcome set.6,29 For example, only
one-third of trials have reported eclampsia, less than a
tenth of trials have reported stroke and only three trials
have reported pulmonary oedema.6 Selective reporting of
outcomes, based on statistical significance could be con-
tributing to these omissions.30 Systematic implementation
of the core outcome set for pre-eclampsia should ensure
future pre-eclampsia research reports outcomes that matter
to healthcare professionals, researchers and women with
pre-eclampsia, and help to limit selective reporting of
results based upon statistical significance. Such an approach
could be replicated in other areas of the health of women
and newborn infants, including endometriosis, twin–twin
transfusion syndrome and neonatal care, to tackle the vari-
ation in outcome reporting and suspected outcome-report-
ing bias.31–33
It is considered good practice for researchers planning
randomised trials to implement the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
statement which outlines the scientific, ethical and adminis-
trative elements that should be addressed in a clinical trial
protocol.34 This statement specifically recommends the use
of core outcome sets where they exist. In addition, the
importance of implementing core outcome sets is recog-
nised by the funders of health research.
The CROWN initiative, supported by over 80 specialty
journals, have resolved to implement this core outcome
set.8 Participating journals will require researchers to report
core outcomes within manuscripts and offer conclusions
based on these outcomes. Where core outcome sets have
not been collected, the researchers will be asked to report
this deficiency and its implications for their findings.9
The Cochrane Pregnancy and Childbirth Group have
committed to implementing the core outcome set for pre-
eclampsia when new and updated reviews are being pre-
pared. Uptake of the core outcome set should facilitate the
possibility of more sophisticated methods of evidence syn-
thesis, including individual patient data meta-analysis and
network meta-analysis.
The core outcome set has been developed specifically for
comparative effectiveness research. The use of this core
outcome set in other types of research is highly desirable.
There is currently a research priority setting partnership
developing research priorities for hypertension in preg-
nancy.35 This work should be considered complementary to
a wider agenda of reducing research waste across hyperten-
sion in pregnancy research. Such agendas have been
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proposed in areas relevant to women’s health, including
twin and multiple pregnancy research with research priority
setting and core outcome set development as important
components.36,37
Blood pressure and severe hypertension were not identi-
fied as core outcomes. In adult non-pregnant populations,
blood pressure is a valid surrogate outcome for heart dis-
ease, stroke and mortality.38–40 In the context of pre-
eclampsia research, maternal blood pressure has been com-
monly selected as a surrogate outcome, which represents a
single pathway that operates within a complex multifacto-
rial disease, characterised by vasoconstriction, coagulation
and intravascular fluid redistribution, resulting in wide-
spread formation of microthrombi and necrosis within
maternal end organs.6,41,42 Reliable conclusions around the
impact of pre-eclampsia interventions cannot necessarily be
informed by reductions in maternal blood pressure because
the consequences of blood pressure changes upon a diverse
range of clinically meaningful outcomes, including mater-
nal mortality, pulmonary oedema and renal failure, may be
unclear. Developing a core outcome set for pre-eclampsia
represents an opportunity to deliver a paradigm shift by
measuring treatment effectiveness as a clinical rather than a
biological response. Researchers should continue to report
blood pressure as a descriptive outcome.
Core outcomes require standardised outcome measures.
Without a standardised approach, researchers would be
able to choose from a variety of different outcome mea-
sures for individual core outcomes. Such variation can
make it difficult to synthesise the results of individual trials
within secondary research.36 The collaboration has stan-
dardised definitions using formal consensus development
methods to secure additional harmony across future pre-
eclampsia trials and ensure that secondary research can be
undertaken prospectively, efficiently and harmoniously.43 It
is intended that these consensus outcome measures will be
used for core outcomes included in other core outcome
sets relevant to the health of women and newborn
infants.44–50
Conclusion
This core outcome set for pre-eclampsia should now under-
pin all future randomised trials and systematic reviews evalu-
ating potential treatments for pre-eclampsia. Such
rationalisation should ensure that future research addresses
outcomes agreed as important in a consistent manner, facili-
tate meta-analysis, enhance patient care and ultimately
improve the outcomes of pregnant women and their babies.
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